Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
V. Lunerti, Q. Shen, H. Li, F. Benvenuti, L. Soverchia, R. Narendran, F. Weiss, N. Cannella, R. Ciccocioppo
This study evaluates cebranopadol's efficacy and abuse liability in treating opioid use disorder using rat models, showing reduced self-administration and stress-induced reinstatement compared to heroin.
bioRxiv · Jul 21, 2023 · PreprintPharmacology & Toxicology